🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Is slow heart rate or conduction block heritable? Check out our new meta-analysis Nature Genetics incl common (~1.3m individuals) + rare (~400k) variants for bradyarrhythmias and conduction dz. Co-led w/ Lu-Chen Weng Joel Rämö Sean Jurgens Broad Institute ! nature.com/articles/s4158…

How lean is your muscle? Hot off the press 🔥European Society of Cardiology We show fatty muscle (IMAT) ⬆️ heart disease risk (beyond fat under skin, around heart or in liver) Ana Carolina Souza Muscle quantity AND quality💪 ⬆️⬆️🫀cardiometabolic risk 👀 👇 bit.ly/42maQXZ bit.ly/3Ce2iYC

The relationship of high polygenic risk scores to coronary artery disease disease for extent of atherosclerosis and presentation with heart attack/unstable angina jamanetwork.com/journals/jaman… JAMA Network Open Akl Fahed Kelvin Supriami Pradeep Natarajan Patrick Ellinor

Delighted to share our study by Sarah Urbut with Akl Fahed on adding in a CAD polygenic risk score to clinical factors to boost CAD risk prediction, particularly for recovering premature CAD events ahajournals.org/doi/10.1161/CI… Circulation: Genomic and Precision Medicine

Exciting to see a series of human genetic observations we made a few years back now moving into therapeutic space ALK7 loss of function mutations, better body fat distribution, reduced T2D risk --> ArrowheadPharma siRNA, pre-clinical data confirming above, to Phase 1 this year

Excited to share our latest publication where we identified a novel and essential role of TTN enhancer. Thanks to Meraj Neyazi, MD Konstantinos Gkatzis Zolt Arany Arun Sharma Christopher Toepfer Dr. Gavin Oudit williampu @AxelVisel.bsky.social Brigham and Women's Hospital Harvard Medical School Brigham and Women’s Cardiovascular Life Science and all others #Genetics

Defended my master’s thesis few days ago! Couldn’t have reached this point without continuous guidance from my mentor Akl Fahed, colleagues Sarah Urbut Christian Faaborg Andersen MD Michael Honigberg, MD, MPP and many people who have supported me so far. Looking forward to continue doing this!

Verve Therapeutics team is thrilled today to present initial data from the Heart-2 Phase 1b clinical trial of VERVE-102, an in vivo base editing investigational medicine targeting PCSK9 And the emerging product profile of VERVE-102 (for patients receiving ≥50mg total RNA dose): a. A

HUGE congrats to graduating MGH Cardiology Fellows Sarah Urbut Sumeet Khetarpal, both 🌟 preventive cardiologist-scientists, for receiving Burroughs Wellcome Fund Career Awards for Medical Scientists!! We are thrilled that Sarah Urbut will stay with us Mass General Heart Broad Institute & also

Today, we are thrilled to announce that Verve Therapeutics has entered into a definitive agreement to be acquired by Eli Lilly and Company From 2018 to 2025, Verve moved a new concept (a one-dose future for the treatment of atherosclerotic cardiovascular disease) and a new medical technology (in

Our study led by R. Bhattacharya & Chris Marnell shows that, when simultaneously considering clinical, laboratory, and genetic risk factors for incident CAD prediction, the top 2 model explanatory factors are: 1. Hypertension 2. CAD polygenic risk score ahajournals.org/doi/10.1161/CI…